FR21C1007I1 - Arnm stabilise avec un contenu augmente en g/c, codant pour un antigene virale - Google Patents

Arnm stabilise avec un contenu augmente en g/c, codant pour un antigene virale

Info

Publication number: FR21C1007I1
Authority: FR; France
Prior art keywords: encoding; increased; content; viral antigen; stabilized mrna
Prior art date: 2001-06-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1007C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Curevac SE

Original Assignee

Curevac AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-05

Filing date

2021-02-15

Publication date

2021-03-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7687266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-02-15 Application filed by Curevac AG filed Critical Curevac AG

2021-03-26 Publication of FR21C1007I1 publication Critical patent/FR21C1007I1/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1735—Mucins, e.g. human intestinal mucin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001196—Fusion proteins originating from gene translocation in cancer cells
- A61K39/001197—Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16071—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Communicable Diseases (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Medical Informatics (AREA)
Spectroscopy & Molecular Physics (AREA)

FR21C1007C 2001-06-05 2021-02-15 Arnm stabilise avec un contenu augmente en g/c, codant pour un antigene virale Active FR21C1007I1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10127283		2001-06-05
EP02732752A EP1392341B1 (de)	2001-06-05	2002-06-05	Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
EP05004938A EP1604688B1 (de)	2001-06-05	2002-06-05	Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt

Publications (1)

Publication Number	Publication Date
FR21C1007I1 true FR21C1007I1 (fr)	2021-03-26

Family

ID=7687266

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR21C1007C Active FR21C1007I1 (fr)	2001-06-05	2021-02-15	Arnm stabilise avec un contenu augmente en g/c, codant pour un antigene virale
FR21C1008C Active FR21C1008I1 (fr)	2001-06-05	2021-02-15	Arnm stabilise avec un contenu augmente en g/c, codant pour un antigene virale

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FR21C1008C Active FR21C1008I1 (fr)	2001-06-05	2021-02-15	Arnm stabilise avec un contenu augmente en g/c, codant pour un antigene virale

Country Status (11)

Country	Link
US (14)	US10188748B2 (es)
EP (8)	EP1903054A3 (es)
AT (5)	ATE456959T1 (es)
AU (2)	AU2007203181B2 (es)
CA (2)	CA2457959C (es)
DE (5)	DE50214200D1 (es)
DK (1)	DK1857122T3 (es)
ES (5)	ES2340532T3 (es)
FR (2)	FR21C1007I1 (es)
PT (1)	PT1857122E (es)
WO (1)	WO2002098443A2 (es)

Families Citing this family (433)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2340532T3 (es)	2001-06-05	2010-06-04	Curevac Gmbh	Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo.
DE10162480A1 (de)	2001-12-19	2003-08-07	Ingmar Hoerr	Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) *	2002-01-18	2003-07-30	Curevac Gmbh	Immunogenic preparations and vaccines on the basis of mrna
FR2845918A1 (fr) *	2002-10-16	2004-04-23	Pasteur Institut	Preparations immunogenes et vaccinantes a base d'arn
DK1519714T3 (da)	2002-06-28	2011-01-31	Protiva Biotherapeutics Inc	Fremgangsmåde og apparat til fremstilling af liposomer
DE10229872A1 (de) *	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
AU2002953015A0 (en) *	2002-12-02	2002-12-12	Women's And Children's Hospital	Modified lacz gene
DE10335833A1 (de) *	2003-08-05	2005-03-03	Curevac Gmbh	Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE10347710B4 (de)	2003-10-14	2006-03-30	Johannes-Gutenberg-Universität Mainz	Rekombinante Impfstoffe und deren Verwendung
US7615618B2 (en) *	2004-06-30	2009-11-10	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a non-phosphate backbone linkage
DE102004035227A1 (de) *	2004-07-21	2006-02-16	Curevac Gmbh	mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de) *	2004-09-02	2006-03-09	Curevac Gmbh	Kombinationstherapie zur Immunstimulation
EP1799823B9 (en) *	2004-09-17	2010-09-15	Institut Pasteur	Method for modulating the evolution of a polypeptide encoded by a nucleic acid sequence
DE102005023170A1 (de) *	2005-05-19	2006-11-23	Curevac Gmbh	Optimierte Formulierung für mRNA
ES2937245T3 (es)	2005-08-23	2023-03-27	Univ Pennsylvania	ARN que contiene nucleósidos modificados y métodos de uso del mismo
EP1764091B1 (en)	2005-09-15	2017-08-30	Marina Biotech, Inc.	Improvements in or relating to amphoteric liposomes
DE102005046490A1 (de)	2005-09-28	2007-03-29	Johannes-Gutenberg-Universität Mainz	Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
JP2010507361A (ja)	2006-07-31	2010-03-11	キュアバックゲーエムベーハー	具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
WO2008105814A2 (en) *	2006-08-22	2008-09-04	Los Alamos National Security, Llc	Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
US8980561B1 (en) *	2006-08-22	2015-03-17	Los Alamos National Security, Llc.	Nucleic acid detection system and method for detecting influenza
JP5424885B2 (ja)	2006-10-13	2014-02-26	マリーナバイオテック，インコーポレイテッド	両性リポソームにおけるまたは両性リポソームに関する改善、両性リポソームを処方する方法および両性リポソームに充填する方法
DE102006051516A1 (de) *	2006-10-31	2008-05-08	Curevac Gmbh	(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
DE102007001370A1 (de)	2007-01-09	2008-07-10	Curevac Gmbh	RNA-kodierte Antikörper
DE102007029471A1 (de)	2007-06-20	2008-12-24	Novosom Ag	Neue fakultativ kationische Sterole
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009039198A2 (en) *	2007-09-17	2009-03-26	The Trustees Of The University Of Pennsylvania	Generation of hyperstable mrnas
WO2009046739A1 (en) *	2007-10-09	2009-04-16	Curevac Gmbh	Composition for treating prostate cancer (pca)
EP3222290A1 (en)	2007-10-09	2017-09-27	CureVac AG	Composition for treating prostate cancer (pca)
WO2009046738A1 (en)	2007-10-09	2009-04-16	Curevac Gmbh	Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
BRPI0820959A2 (pt) *	2007-12-05	2017-05-09	Eyegate Pharma S A S	métodos de dispensação de uma quantidade eficaz de sirna via iontoforese transescleral no olho de um paciente e de tratamento de doenças oculares em um mamífero, formulação de sirna, e, dispositivo para dispensação de sirna para o olho de um paciente
MX2010008468A (es)	2008-01-31	2010-08-30	Curevac Gmbh	Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
WO2009127230A1 (en) *	2008-04-16	2009-10-22	Curevac Gmbh	MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
EP2279403B1 (en) *	2008-05-05	2016-03-16	Los Alamos National Security, LLC	Highly simplified lateral flow-based nucleic acid sample preparation and passive fluid flow control
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN201397956Y (zh) *	2009-03-23	2010-02-03	富士康(昆山)电脑接插件有限公司	电连接器组件
US20120237589A1 (en)	2009-07-09	2012-09-20	Marina Biotech, Inc.	Amphoteric liposomes comprising imino lipids
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
AU2010326132B9 (en)	2009-12-01	2014-10-02	Translate Bio, Inc.	Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
WO2011069529A1 (en)	2009-12-09	2011-06-16	Curevac Gmbh	Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
WO2011069528A1 (en)	2009-12-09	2011-06-16	Curevac Gmbh	Lyophilization of nucleic acids in lactate-containing solutions
SI3243526T1 (sl)	2010-07-06	2020-02-28	Glaxosmithkline Biologicals S.A.	Dostava RNA za sprožitev večih imunskih poti
JP5940064B2 (ja)	2010-07-06	2016-06-29	ノバルティスアーゲー	低用量のｒｎａを用いた大型哺乳動物の免疫化
BR112013000244A2 (pt)	2010-07-06	2016-05-17	Novartis Ag	lipossomas com lipídeos apresentando pka vantajoso para administração de rna
SMT202200500T1 (it)	2010-07-06	2023-01-13	Glaxosmithkline Biologicals Sa	Particelle di rilascio simili a virioni per molecole di rna auto-replicanti
WO2012013326A1 (en)	2010-07-30	2012-02-02	Curevac Gmbh	Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
WO2012019630A1 (en)	2010-08-13	2012-02-16	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
LT4066856T (lt)	2010-08-31	2023-01-25	Glaxosmithkline Biologicals Sa	Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui
SG190679A1 (en)	2010-10-01	2013-07-31	Jason Schrum	Engineered nucleic acids and methods of use thereof
CA2814386C (en)	2010-10-11	2019-08-20	Novartis Ag	Antigen delivery platforms
WO2012075040A2 (en)	2010-11-30	2012-06-07	Shire Human Genetic Therapies, Inc.	mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012089225A1 (en)	2010-12-29	2012-07-05	Curevac Gmbh	Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en)	2011-03-02	2012-09-07	Curevac Gmbh	Vaccination in newborns and infants
WO2012113413A1 (en)	2011-02-21	2012-08-30	Curevac Gmbh	Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en)	2011-03-02	2012-09-07	Curevac Gmbh	Vaccination in elderly patients
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
AU2012234259A1 (en)	2011-03-31	2013-10-03	Libera-Korner, Jeanette	Perfluorinated compounds for the non-viral transfer of nucleic acids
EP2699698B9 (en)	2011-04-20	2020-07-15	Mesa Biotech, Inc.	Oscillating amplification reaction for nucleic acids
SMT201900521T1 (it) *	2011-05-24	2019-11-13	Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh	Vaccini individualizzati per il cancro
SMT202300161T1 (it)	2011-05-24	2023-07-20	Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh	Vaccini individualizzati per il cancro
EP4458350A3 (en)	2011-06-08	2025-01-22	Translate Bio, Inc.	Lipid nanoparticle compositions and methods for mrna delivery
EP3332802A1 (en)	2011-07-06	2018-06-13	GlaxoSmithKline Biologicals SA	Immunogenic combination compositions and uses thereof
JP2014520806A (ja) *	2011-07-06	2014-08-25	ノバルティスアーゲー	Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RU2707251C2 (ru)	2011-10-03	2019-11-25	Модерна Терапьютикс, Инк.	Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
WO2013090648A1 (en)	2011-12-16	2013-06-20	modeRNA Therapeutics	Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120498A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120500A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
PL2814962T3 (pl)	2012-02-15	2018-11-30	Curevac Ag	Kwas nukleinowy zawierający lub kodujący histonowy trzonek-pętlę i sekwencję poli(A) lub sygnał poliadenylacji do zwiększania ekspresji zakodowanego antygenu patogennego
EP3527662B1 (en)	2012-02-15	2022-01-26	CureVac AG	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
EP3404103B1 (en)	2012-02-15	2021-03-24	CureVac AG	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120499A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en)	2012-02-15	2013-08-22	Curevac Gmbh	Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013143555A1 (en)	2012-03-26	2013-10-03	Biontech Ag	Rna formulation for immunotherapy
MX362981B (es)	2012-03-27	2019-02-28	Curevac Ag	Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
KR20140139101A (ko)	2012-03-27	2014-12-04	큐어백 게엠바하	5''top utr을 포함하는 인공 핵산 분자
EP3578659B1 (en)	2012-03-27	2023-11-01	CureVac SE	Artificial nucleic acid molecules for improved protein or peptide expression
AU2013242403B2 (en)	2012-03-27	2018-10-18	Curevac Ag	Artificial nucleic acid molecules
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
JP2015513913A (ja)	2012-04-02	2015-05-18	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ポリヌクレオチド
US10501513B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243949A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of biologics and proteins associated with human disease
US9649208B2 (en)	2012-04-13	2017-05-16	Medtronic Vascular, Inc.	Hollow drug-filled stent and method of forming hollow drug-filled stent
US8998977B2 (en)	2012-04-13	2015-04-07	Medtronic Vascular, Inc.	Hollow drug-filled stent and method of forming hollow drug-filled stent
US20150267192A1 (en)	2012-06-08	2015-09-24	Shire Human Genetic Therapies, Inc.	Nuclease resistant polynucleotides and uses thereof
EP2885419A4 (en)	2012-08-14	2016-05-25	Moderna Therapeutics Inc	ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
JP6144355B2 (ja) *	2012-11-26	2017-06-07	モデルナティエックスインコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ．	化学修飾ｍＲＮＡ
US10155031B2 (en)	2012-11-28	2018-12-18	Biontech Rna Pharmaceuticals Gmbh	Individualized vaccines for cancer
EP3434774A1 (en)	2013-01-17	2019-01-30	ModernaTX, Inc.	Signal-sensor polynucleotides for the alteration of cellular phenotypes
EP2765137A1 (en)	2013-02-07	2014-08-13	Sanofi Pasteur	Induction of cross-reactive cellular response against rhinovirus antigens
MX2015010880A (es)	2013-02-22	2015-12-03	Curevac Gmbh	Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
EP3578200A1 (en)	2013-02-22	2019-12-11	CureVac AG	Combination of vaccination and inhibition of the pd-1 pathway
US20160032316A1 (en)	2013-03-14	2016-02-04	The Trustees Of The University Of Pennsylvania	Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
HUE042640T2 (hu)	2013-03-14	2019-07-29	Translate Bio Inc	CFTR-mRNS-készítmények, valamint kapcsolódó eljárások és alkalmazások
EP2970955B1 (en)	2013-03-14	2018-11-14	Translate Bio, Inc.	Methods for purification of messenger rna
EP2971010B1 (en)	2013-03-14	2020-06-10	ModernaTX, Inc.	Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10077439B2 (en)	2013-03-15	2018-09-18	Modernatx, Inc.	Removal of DNA fragments in mRNA production process
EP4279610A3 (en)	2013-03-15	2024-01-03	ModernaTX, Inc.	Ribonucleic acid purification
WO2014144767A1 (en)	2013-03-15	2014-09-18	Moderna Therapeutics, Inc.	Ion exchange purification of mrna
WO2014180490A1 (en)	2013-05-10	2014-11-13	Biontech Ag	Predicting immunogenicity of t cell epitopes
WO2014201252A2 (en)	2013-06-13	2014-12-18	Shire Human Genetic Therapies, Inc.	Messenger rna based viral production
LT3019619T (lt)	2013-07-11	2021-12-10	Modernatx, Inc.	Sintetinius polinukleotidus apimančios kompozicijos, koduojančios susijusius su crispr baltymus ir sintetines sgrnas, ir jų naudojimo būdai
WO2015024669A1 (en)	2013-08-21	2015-02-26	Curevac Gmbh	Combination vaccine
EP3574916A1 (en)	2013-08-21	2019-12-04	CureVac AG	Composition and vaccine for treating lung cancer
CN105517569A (zh)	2013-08-21	2016-04-20	库瑞瓦格股份公司	狂犬病疫苗
CA2915724C (en) *	2013-08-21	2023-09-26	Patrick Baumhof	Method for increasing expression of rna-encoded proteins
KR20160044566A (ko)	2013-08-21	2016-04-25	큐어백 아게	호흡기 세포융합 바이러스
EP3036330B1 (en) *	2013-08-21	2018-09-12	CureVac AG	Method for increasing expression of rna-encoded proteins
EP3041934A1 (en)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Chimeric polynucleotides
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
EP3052106A4 (en)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3052511A4 (en)	2013-10-02	2017-05-31	Moderna Therapeutics, Inc.	Polynucleotide molecules and uses thereof
CN105980401A (zh)	2013-10-03	2016-09-28	现代治疗公司	编码低密度脂蛋白受体的多核苷酸
CA2928186A1 (en)	2013-10-22	2015-04-30	Shire Human Genetic Therapies, Inc.	Mrna therapy for phenylketonuria
AU2014340092B2 (en)	2013-10-22	2019-09-19	Translate Bio, Inc.	mRNA therapy for Argininosuccinate Synthetase Deficiency
SG11201602625YA (en)	2013-11-01	2016-05-30	Pfizer	Vectors for expression of prostate-associated antigens
EP3542802A1 (en)	2013-11-01	2019-09-25	CureVac AG	Modified rna with decreased immunostimulatory properties
CA2925021A1 (en)	2013-11-01	2015-05-07	Curevac Ag	Modified rna with decreased immunostimulatory properties
JP6584414B2 (ja)	2013-12-30	2019-10-02	キュアバックアーゲー	人工核酸分子
EP3842537A1 (en)	2013-12-30	2021-06-30	CureVac AG	Artificial nucleic acid molecules
AU2014375404C1 (en)	2013-12-30	2020-11-19	CureVac Manufacturing GmbH	Methods for RNA analysis
SG11201603144QA (en)	2013-12-30	2016-07-28	Curevac Ag	Artificial nucleic acid molecules
US11254951B2 (en)	2014-12-30	2022-02-22	Curevac Ag	Artificial nucleic acid molecules
EP3415629A1 (en) *	2013-12-30	2018-12-19	CureVac AG	Artificial nucleic acid molecules
CA2935878C (en)	2014-03-12	2023-05-02	Curevac Ag	Combination of vaccination and ox40 agonists
CA2936286A1 (en)	2014-04-01	2015-10-08	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
LT4023249T (lt)	2014-04-23	2025-01-10	Modernatx, Inc.	Nuleorūgšties vakcinos
PT3134506T (pt)	2014-04-25	2019-10-31	Translate Bio Inc	Métodos de purificação de rna mensageiro
US20180010136A1 (en) *	2014-05-30	2018-01-11	John Francis Hunt, III	Methods for Altering Polypeptide Expression
WO2015188933A1 (en)	2014-06-10	2015-12-17	Curevac Ag	Methods and means for enhancing rna production
US10286086B2 (en)	2014-06-19	2019-05-14	Modernatx, Inc.	Alternative nucleic acid molecules and uses thereof
US10407683B2 (en)	2014-07-16	2019-09-10	Modernatx, Inc.	Circular polynucleotides
CA2955250A1 (en)	2014-07-16	2016-01-21	Moderna Therapeutics, Inc.	Chimeric polynucleotides
JP6824594B2 (ja)	2014-09-11	2021-02-03	Jnc株式会社	合成遺伝子の設計方法
WO2016045732A1 (en)	2014-09-25	2016-03-31	Biontech Rna Pharmaceuticals Gmbh	Stable formulations of lipids and liposomes
EP4324473A3 (en)	2014-11-10	2024-05-29	ModernaTX, Inc.	Multiparametric nucleic acid optimization
EP3041948B1 (en)	2014-11-10	2019-01-09	Modernatx, Inc.	Alternative nucleic acid molecules containing reduced uracil content and uses thereof
WO2016086988A1 (en) *	2014-12-03	2016-06-09	Wageningen Universiteit	Optimisation of coding sequence for functional protein expression
PT3708668T (pt)	2014-12-12	2022-09-14	Curevac Ag	Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
US20180148727A1 (en)	2014-12-30	2018-05-31	Curevac Ag	Artificial nucleic acid molecules
WO2016128060A1 (en)	2015-02-12	2016-08-18	Biontech Ag	Predicting t cell epitopes useful for vaccination
EP3283059B1 (en)	2015-04-13	2024-01-03	CureVac Manufacturing GmbH	Method for producing rna compositions
US10780054B2 (en)	2015-04-17	2020-09-22	Curevac Real Estate Gmbh	Lyophilization of RNA
US10293058B2 (en) *	2015-04-22	2019-05-21	Curevac Ag	RNA containing composition for treatment of tumor diseases
CN118788410A (zh)	2015-04-24	2024-10-18	美飒生物技术公司	流体检测盒
JP2018526321A (ja)	2015-04-27	2018-09-13	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
US11384375B2 (en)	2015-04-30	2022-07-12	Curevac Ag	Immobilized poly(n)polymerase
DK3294885T3 (da)	2015-05-08	2020-08-10	Curevac Real Estate Gmbh	Fremgangsmåde til at fremstille rna
JP6893177B2 (ja)	2015-05-15	2021-06-23	キュアバックアーゲー	少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴＲＥＧＩＭＥＮＳ）
US20200317764A1 (en) *	2015-05-19	2020-10-08	Morphogenesis, Inc.	Modified mrna for multicell transformation
WO2016184575A1 (en)	2015-05-20	2016-11-24	Curevac Ag	Dry powder composition comprising long-chain rna
US10729654B2 (en)	2015-05-20	2020-08-04	Curevac Ag	Dry powder composition comprising long-chain RNA
US10760070B2 (en)	2015-05-29	2020-09-01	Curevac Real Estate Gmbh	Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
US11608513B2 (en)	2015-05-29	2023-03-21	CureVac SE	Method for adding cap structures to RNA using immobilized enzymes
WO2017009376A1 (en)	2015-07-13	2017-01-19	Curevac Ag	Method of producing rna from circular dna and corresponding template dna
EP4218805A1 (en)	2015-07-21	2023-08-02	ModernaTX, Inc.	Infectious disease vaccines
US11364292B2 (en)	2015-07-21	2022-06-21	Modernatx, Inc.	CHIKV RNA vaccines
WO2017020026A1 (en)	2015-07-30	2017-02-02	Modernatx, Inc.	Concatemeric peptide epitopes rnas
DK3341482T3 (da)	2015-08-28	2022-08-15	Curevac Ag	Kunstige nukleinsyremolekyler
WO2017036889A1 (en)	2015-08-28	2017-03-09	Biontech Rna Pharmaceuticals Gmbh	Method for reducing immunogenicity of rna
EP3736261B1 (en)	2015-09-17	2023-10-11	ModernaTX, Inc.	Compounds and compositions for intracellular delivery of therapeutic agents
AU2016324463B2 (en)	2015-09-17	2022-10-27	Modernatx, Inc.	Polynucleotides containing a stabilizing tail region
WO2017049286A1 (en)	2015-09-17	2017-03-23	Moderna Therapeutics, Inc.	Polynucleotides containing a morpholino linker
US10849920B2 (en)	2015-10-05	2020-12-01	Modernatx, Inc.	Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017059902A1 (en) *	2015-10-07	2017-04-13	Biontech Rna Pharmaceuticals Gmbh	3' utr sequences for stabilization of rna
US11225682B2 (en)	2015-10-12	2022-01-18	Curevac Ag	Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
WO2017066782A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Hydrophobic mrna cap analogs
WO2017066789A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Mrna cap analogs with modified sugar
WO2017066793A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Mrna cap analogs and methods of mrna capping
WO2017066791A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Sugar substituted mrna cap analogs
DK3362461T3 (da)	2015-10-16	2022-05-09	Modernatx Inc	Mrna-cap-analoger med modificeret phosphatbinding
WO2017066797A1 (en)	2015-10-16	2017-04-20	Modernatx, Inc.	Trinucleotide mrna cap analogs
JP7384512B2 (ja)	2015-10-22	2023-11-21	モデルナティエックスインコーポレイテッド	広域インフルエンザウイルスワクチン
SG11201803365RA (en)	2015-10-22	2018-05-30	Modernatx Inc	Herpes simplex virus vaccine
AU2016342045A1 (en)	2015-10-22	2018-06-07	Modernatx, Inc.	Human cytomegalovirus vaccine
WO2017070616A2 (en)	2015-10-22	2017-04-27	Modernatx, Inc.	Sexually transmitted disease vaccines
BR112018008102A2 (pt)	2015-10-22	2018-11-06	Modernatx Inc	vacina de vírus sincicial respiratório
MA47016A (fr)	2015-10-22	2018-08-29	Modernatx Inc	Vaccins contre les virus respiratoires
CN108472309A (zh)	2015-10-22	2018-08-31	摩登纳特斯有限公司	用于水痘带状疱疹病毒（vzv）的核酸疫苗
EP3364950A4 (en)	2015-10-22	2019-10-23	ModernaTX, Inc.	VACCINES AGAINST TROPICAL DISEASES
US20180312545A1 (en) *	2015-11-09	2018-11-01	Curevac Ag	Optimized nucleic acid molecules
WO2017081110A1 (en)	2015-11-09	2017-05-18	Curevac Ag	Rotavirus vaccines
SG11201804398XA (en)	2015-12-22	2018-07-30	Curevac Ag	Method for producing rna molecule compositions
AU2016377681B2 (en)	2015-12-22	2021-05-13	Modernatx, Inc.	Compounds and compositions for intracellular delivery of agents
EP3394280A1 (en)	2015-12-23	2018-10-31	CureVac AG	Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
CN113181106A (zh)	2016-01-11	2021-07-30	沃达瑞公司	微针组合物及其使用方法
WO2017127750A1 (en)	2016-01-22	2017-07-27	Modernatx, Inc.	Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
EP4289965A3 (en)	2016-02-12	2024-02-21	CureVac SE	Method for analyzing rna
US11723967B2 (en)	2016-02-17	2023-08-15	CureVac SE	Zika virus vaccine
EP3423595A1 (en)	2016-03-03	2019-01-09	CureVac AG	Rna analysis by total hydrolysis
US11446398B2 (en)	2016-04-11	2022-09-20	Obsidian Therapeutics, Inc.	Regulated biocircuit systems
EP4487869A2 (en)	2016-04-22	2025-01-08	CureVac SE	Rna encoding a tumor antigen
WO2017186928A1 (en)	2016-04-29	2017-11-02	Curevac Ag	Rna encoding an antibody
EP3452101A2 (en)	2016-05-04	2019-03-13	CureVac AG	Rna encoding a therapeutic protein
EP4477662A2 (en)	2016-05-04	2024-12-18	CureVac SE	Nucleic acid molecules and uses thereof
US20210162037A1 (en) *	2016-05-04	2021-06-03	Curevac Ag	Influenza mrna vaccines
EP3458104A1 (en)	2016-05-18	2019-03-27	Modernatx, Inc.	Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
US20190298657A1 (en)	2016-05-18	2019-10-03	Modernatx, Inc.	Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
IL263079B2 (en)	2016-05-18	2024-05-01	Modernatx Inc	Polynucleotides encoding relaxin
JP7246930B2 (ja)	2016-05-18	2023-03-28	モデルナティエックスインコーポレイテッド	インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用
EP3896164A1 (en)	2016-05-18	2021-10-20	ModernaTX, Inc.	Polynucleotides encoding alpha-galactosidase a for the treatment of fabry disease
MA45052A (fr)	2016-05-18	2019-03-27	Modernatx Inc	Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
WO2017201348A1 (en)	2016-05-18	2017-11-23	Modernatx, Inc.	Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
CN116726203A (zh)	2016-05-18	2023-09-12	莫得纳特斯公司	编码免疫调节多肽的mrna的组合及其用途
WO2017201349A1 (en)	2016-05-18	2017-11-23	Modernatx, Inc.	Polynucleotides encoding citrin for the treatment of citrullinemia type 2
US20190336608A1 (en)	2016-06-09	2019-11-07	Curevac Ag	Cationic carriers for nucleic acid delivery
JP7145579B2 (ja)	2016-06-09	2022-10-03	キュアバックアーゲー	核酸カーゴ用のハイブリッド担体
US20190336611A1 (en)	2016-06-09	2019-11-07	Curevac Ag	Hybrid carriers for nucleic acid cargo
EP3468537A1 (en)	2016-06-14	2019-04-17	Modernatx, Inc.	Stabilized formulations of lipid nanoparticles
SG10201913631TA (en)	2016-08-19	2020-03-30	Curevac Ag	Rna for cancer therapy
WO2018041921A1 (en)	2016-08-31	2018-03-08	Curevac Ag	Mixing device for the production of a liquid nucleic acid composition
CA3041307A1 (en)	2016-10-21	2018-04-26	Giuseppe Ciaramella	Human cytomegalovirus vaccine
US20200163878A1 (en)	2016-10-26	2020-05-28	Curevac Ag	Lipid nanoparticle mrna vaccines
WO2018089540A1 (en)	2016-11-08	2018-05-17	Modernatx, Inc.	Stabilized formulations of lipid nanoparticles
WO2018087276A1 (en)	2016-11-10	2018-05-17	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Or10h1 modulators and uses thereof
EP3538146A4 (en)	2016-11-11	2020-07-15	ModernaTX, Inc.	INFLUENZA VACCINE
US11279923B2 (en)	2016-11-28	2022-03-22	Curevac Ag	Method for purifying RNA
JP2019535839A (ja)	2016-11-29	2019-12-12	ピュアテックヘルスエルエルシー	治療剤の送達のためのエクソソーム
US11542490B2 (en)	2016-12-08	2023-01-03	CureVac SE	RNAs for wound healing
EP3551193A4 (en)	2016-12-08	2020-08-19	Modernatx, Inc.	NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
CN110582304A (zh)	2016-12-08	2019-12-17	库尔维科公司	用于治疗或预防肝脏疾病的rna
EP3558356A2 (en)	2016-12-23	2019-10-30	CureVac AG	Mers coronavirus vaccine
US11464847B2 (en)	2016-12-23	2022-10-11	Curevac Ag	Lassa virus vaccine
EP3558355A2 (en)	2016-12-23	2019-10-30	CureVac AG	Henipavirus vaccine
US11241490B2 (en)	2017-01-11	2022-02-08	The Trustees Of The University Of Pennsylvania	Nucleoside-modified RNA for inducing an immune response against zika virus
WO2018144778A1 (en)	2017-02-01	2018-08-09	Modernatx, Inc.	Polynucleotide secondary structure
KR20190110612A (ko)	2017-02-01	2019-09-30	모더나티엑스, 인크.	활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물
MA47515A (fr)	2017-02-16	2019-12-25	Modernatx Inc	Compositions immunogènes très puissantes
MX2019010155A (es)	2017-02-27	2020-12-10	Translate Bio Inc	Arnm de cftr optimizado por codón novedoso.
US11407800B2 (en)	2017-02-28	2022-08-09	Arcturus Therapeutics, Inc.	Translatable molecules and synthesis thereof
JP6949131B2 (ja)	2017-02-28	2021-10-13	サノフイＳａｎｏｆｉ	治療用ｒｎａ
MA47787A (fr)	2017-03-15	2020-01-22	Modernatx Inc	Vaccin contre le virus respiratoire syncytial
DK3596041T3 (da)	2017-03-15	2023-01-23	Modernatx Inc	Forbindelse og sammensætninger til intracellulær afgivelse af terapeutiske midler
WO2018170245A1 (en)	2017-03-15	2018-09-20	Modernatx, Inc.	Broad spectrum influenza virus vaccine
US11752206B2 (en)	2017-03-15	2023-09-12	Modernatx, Inc.	Herpes simplex virus vaccine
EP3595727B1 (en)	2017-03-15	2024-11-27	ModernaTX, Inc.	Lipid nanoparticle formulation
US11045540B2 (en)	2017-03-15	2021-06-29	Modernatx, Inc.	Varicella zoster virus (VZV) vaccine
CN110392577A (zh)	2017-03-17	2019-10-29	库尔维科公司	用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
WO2018170347A1 (en)	2017-03-17	2018-09-20	Modernatx, Inc.	Zoonotic disease rna vaccines
MX2019011215A (es)	2017-03-24	2020-02-12	Curevac Ag	Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
AU2018246292A1 (en)	2017-03-31	2019-10-10	Accanis Biotech F&E Gmbh & Co Kg	Prevention and treatment of non-melanoma skin cancer (NMSC)
WO2018187590A1 (en)	2017-04-05	2018-10-11	Modernatx, Inc.	Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US11357856B2 (en)	2017-04-13	2022-06-14	Acuitas Therapeutics, Inc.	Lipids for delivery of active agents
EP3615054A4 (en)	2017-04-27	2021-03-24	The Trustees Of The University Of Pennsylvania	NUCLEOSIDE MODIFIED MRNA-LIPID NANOPARTICLE LINE VACCINE FOR THE HEPATITIS C VIRUS
US11173190B2 (en)	2017-05-16	2021-11-16	Translate Bio, Inc.	Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
AU2018270111B2 (en)	2017-05-18	2022-07-14	Modernatx, Inc.	Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
MX2019014412A (es)	2017-05-31	2020-02-10	Ultragenyx Pharmaceutical Inc	Productos terapeuticos para la enfermedad de almacenamiento de glucogeno de tipo iii.
US12077501B2 (en)	2017-06-14	2024-09-03	Modernatx, Inc.	Compounds and compositions for intracellular delivery of agents
EP3424524B1 (en)	2017-07-04	2024-12-11	CureVac SE	Cancer rna-vaccine
WO2019036638A1 (en)	2017-08-18	2019-02-21	Modernatx, Inc.	METHODS FOR PREPARING MODIFIED RNA
US11602557B2 (en)	2017-08-22	2023-03-14	Cure Vac SE	Bunyavirales vaccine
JP7275111B2 (ja)	2017-08-31	2023-05-17	モデルナティエックスインコーポレイテッド	脂質ナノ粒子の生成方法
EP3681514A4 (en)	2017-09-14	2021-07-14	ModernaTX, Inc.	RNA VACZINE AGAINST ZIKA VIRUS
KR20200071081A (ko)	2017-10-19	2020-06-18	큐어백 아게	신규 인공 핵산 분자
CN111511924A (zh)	2017-11-08	2020-08-07	库瑞瓦格股份公司	Rna序列调整
WO2019115635A1 (en)	2017-12-13	2019-06-20	Curevac Ag	Flavivirus vaccine
SG11202005760PA (en)	2017-12-21	2020-07-29	Curevac Ag	Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
EP3508499A1 (en)	2018-01-08	2019-07-10	iOmx Therapeutics AG	Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
MA54676A (fr)	2018-01-29	2021-11-17	Modernatx Inc	Vaccins à base d'arn contre le vrs
CN108363904B (zh) *	2018-02-07	2019-06-28	南京林业大学	一种用于木本植物遗传密码子优化的CodonNX系统及其优化方法
US20210361761A1 (en)	2018-04-05	2021-11-25	Curevac Ag	Novel yellow fever nucleic acid molecules for vaccination
US20210170017A1 (en)	2018-04-17	2021-06-10	Curevac Ag	Novel rsv rna molecules and compositions for vaccination
US20220403001A1 (en)	2018-06-12	2022-12-22	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3813874A1 (en)	2018-06-27	2021-05-05	CureVac AG	Novel lassa virus rna molecules and compositions for vaccination
CN112930396B (zh)	2018-08-24	2024-05-24	川斯勒佰尔公司	用于纯化信使rna的方法
EP4509118A2 (en)	2018-09-19	2025-02-19	ModernaTX, Inc.	High-purity peg lipids and uses thereof
CA3113436A1 (en)	2018-09-19	2020-03-26	Modernatx, Inc.	Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061284A1 (en)	2018-09-19	2020-03-26	Modernatx, Inc.	Peg lipids and uses thereof
CN113271926A (zh)	2018-09-20	2021-08-17	摩登纳特斯有限公司	脂质纳米颗粒的制备及其施用方法
EP3870600A1 (en)	2018-10-24	2021-09-01	Obsidian Therapeutics, Inc.	Er tunable protein regulation
AU2019384557A1 (en)	2018-11-21	2021-06-10	Translate Bio, Inc.	Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
PL3891274T3 (pl)	2018-12-06	2024-03-25	Arcturus Therapeutics, Inc.	Kompozycje i sposoby leczenia niedoboru transkarbamylazy ornityny
KR20210105382A (ko)	2018-12-19	2021-08-26	베르사멥 아게	단백질을 코딩하는 rna
US20220040281A1 (en)	2018-12-21	2022-02-10	Curevac Ag	Rna for malaria vaccines
CN113939282A (zh)	2019-01-31	2022-01-14	摩登纳特斯有限公司	制备脂质纳米颗粒的方法
AU2020214425A1 (en)	2019-01-31	2021-08-19	Modernatx, Inc.	Vortex mixers and associated methods, systems, and apparatuses thereof
CA3125511A1 (en)	2019-02-08	2020-08-13	Curevac Ag	Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
US11351242B1 (en)	2019-02-12	2022-06-07	Modernatx, Inc.	HMPV/hPIV3 mRNA vaccine composition
EP3938379A4 (en)	2019-03-15	2023-02-22	ModernaTX, Inc.	Hiv rna vaccines
EP3986452A1 (en)	2019-06-18	2022-04-27	CureVac AG	Rotavirus mrna vaccine
MA56539A (fr) *	2019-06-24	2022-04-27	Modernatx Inc	Arn messager résistant à l'endonucléase et utilisations correspondantes
US20220372138A1 (en)	2019-07-05	2022-11-24	Iomx Therapeutics Ag	Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
CN114502204A (zh)	2019-08-14	2022-05-13	库尔维科公司	具有降低的免疫刺激性质的rna组合和组合物
EP4048692A2 (en)	2019-10-24	2022-08-31	NovaGo Therapeutics AG	Novel anti-nogo-a antibodies
EP3822288A1 (en)	2019-11-18	2021-05-19	Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts	Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
IL293890A (en)	2019-12-20	2022-08-01	Curevac Ag	Lipid nanoparticles for delivery of nucleic acids
CA3168902A1 (en)	2020-01-28	2021-08-05	Modernatx, Inc.	Coronavirus rna vaccines
US12194089B2 (en)	2020-02-04	2025-01-14	CureVac SE	Coronavirus vaccine
AU2021216658A1 (en)	2020-02-04	2022-06-23	CureVac SE	Coronavirus vaccine
US11241493B2 (en)	2020-02-04	2022-02-08	Curevac Ag	Coronavirus vaccine
CN115551545A (zh)	2020-02-07	2022-12-30	摩登纳特斯有限公司	SARS-COV-2 mRNA结构域疫苗
CA3178455A1 (en)	2020-04-09	2021-10-14	Suzhou Abogen Biosciences Co., Ltd.	Lipid nanoparticle composition
CN113874507A (zh)	2020-04-09	2021-12-31	苏州艾博生物科技有限公司	冠状病毒的核酸疫苗
WO2021213924A1 (en)	2020-04-22	2021-10-28	BioNTech SE	Coronavirus vaccine
WO2021222304A1 (en)	2020-04-27	2021-11-04	Modernatx, Inc.	Sars-cov-2 rna vaccines
WO2021159130A2 (en)	2020-05-15	2021-08-12	Modernatx, Inc.	Coronavirus rna vaccines and methods of use
AU2021279312A1 (en)	2020-05-29	2022-12-15	CureVac SE	Nucleic acid based combination vaccines
US20230242624A1 (en)	2020-06-02	2023-08-03	Neurimmune Ag	HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
AU2021301922A1 (en)	2020-06-30	2023-02-02	Suzhou Abogen Biosciences Co., Ltd.	Lipid compounds and lipid nanoparticle compositions
EP4175668A1 (en)	2020-07-06	2023-05-10	iOmx Therapeutics AG	Antibodies binding igv of igsf11 (vsig3) and uses thereof
EP4172194A1 (en)	2020-07-31	2023-05-03	CureVac SE	Nucleic acid encoded antibody mixtures
TW202214566A (zh)	2020-08-20	2022-04-16	大陸商蘇州艾博生物科技有限公司	脂質化合物及脂質奈米粒子組合物
US11406703B2 (en)	2020-08-25	2022-08-09	Modernatx, Inc.	Human cytomegalovirus vaccine
WO2022043551A2 (en)	2020-08-31	2022-03-03	Curevac Ag	Multivalent nucleic acid based coronavirus vaccines
US20230355743A1 (en)	2020-09-25	2023-11-09	Modernatx, Inc.	Multi-proline-substituted coronavirus spike protein vaccines
CN117177766A (zh)	2020-10-26	2023-12-05	佩奇大学	疫苗平台
EP3992205A1 (en)	2020-11-03	2022-05-04	Rheinische Friedrich-Wilhelms-Universität Bonn	Sars coronavirus-2 spike protein binding compounds
CN116635425A (zh)	2020-11-03	2023-08-22	德国癌症研究中心公共法律基金会	靶细胞限制性、共刺激性、双特异性二价抗cd28抗体
WO2022106205A1 (en)	2020-11-18	2022-05-27	Rheinische Friedrich-Wilhelms-Universität Bonn	Corona virus spike protein binding compounds
WO2022106860A1 (en)	2020-11-20	2022-05-27	Pécsi Tudományegyetem	Recombinant peptides for use in therapy
WO2022137133A1 (en)	2020-12-22	2022-06-30	Curevac Ag	Rna vaccine against sars-cov-2 variants
EP4267178A1 (en)	2020-12-22	2023-11-01	CureVac SE	Rna vaccine against sars-cov-2 variants
US20240299309A1 (en)	2020-12-22	2024-09-12	CureVac SE	Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
WO2022150717A1 (en)	2021-01-11	2022-07-14	Modernatx, Inc.	Seasonal rna influenza virus vaccines
CN116615472A (zh)	2021-01-14	2023-08-18	苏州艾博生物科技有限公司	聚合物缀合的脂质化合物和脂质纳米颗粒组合物
WO2022152109A2 (en)	2021-01-14	2022-07-21	Suzhou Abogen Biosciences Co., Ltd.	Lipid compounds and lipid nanoparticle compositions
US20240100151A1 (en)	2021-01-15	2024-03-28	Moderna TX, Inc.	Variant strain-based coronavirus vaccines
EP4277653A1 (en)	2021-01-15	2023-11-22	ModernaTX, Inc.	Variant strain-based coronavirus vaccines
CN112735525B (zh) *	2021-01-18	2023-12-26	苏州科锐迈德生物医药科技有限公司	一种基于分治法的mRNA序列优化的方法与装置
WO2022162027A2 (en)	2021-01-27	2022-08-04	Curevac Ag	Method of reducing the immunostimulatory properties of in vitro transcribed rna
WO2022177597A1 (en) *	2021-02-16	2022-08-25	The Board Of Trustees Of The Leland Stanford Junior University	Systems and methods to enhance rna stability and translation and uses thereof
JP2024510415A (ja)	2021-03-01	2024-03-07	スキロムゲゼルシャフトミットベシュレンクテルハフツング	ｉＲｈｏｍ２に対するヒト化抗体
EP4301402A1 (en)	2021-03-03	2024-01-10	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Bispecific antibodies enhancing cell mediated immune responses
MX2023011227A (es)	2021-03-22	2023-12-06	Recode Therapeutics Inc	Composiciones y metodos para administracion dirigida a celulas.
CA3212653A1 (en)	2021-03-26	2022-09-29	Glaxosmithkline Biologicals Sa	Immunogenic compositions
WO2022207652A1 (en)	2021-03-29	2022-10-06	Scirhom Gmbh	Methods of treatment using protein binders to irhom2 epitopes
EP4312988A2 (en)	2021-03-31	2024-02-07	CureVac SE	Syringes containing pharmaceutical compositions comprising rna
CA3214085A1 (en)	2021-03-31	2022-10-06	Darby Rye Schmidt	Thanotransmission polypeptides and their use in treating cancer
WO2022214664A1 (en)	2021-04-09	2022-10-13	Philogen S.P.A.	Improved interferon-gamma mutant
EP4322993A1 (en)	2021-04-13	2024-02-21	ModernaTX, Inc.	Respiratory virus combination vaccines
EP4322994A1 (en)	2021-04-14	2024-02-21	ModernaTX, Inc.	Influenza-coronavirus combination vaccines
US20240229075A1 (en)	2021-05-03	2024-07-11	CureVac SE	Improved nucleic acid sequence for cell type specific expression
WO2022245888A1 (en)	2021-05-19	2022-11-24	Modernatx, Inc.	Seasonal flu rna vaccines and methods of use
WO2022247755A1 (en)	2021-05-24	2022-12-01	Suzhou Abogen Biosciences Co., Ltd.	Lipid compounds and lipid nanoparticle compositions
US20240342206A1 (en)	2021-07-30	2024-10-17	CureVac SE	mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
CA3227081A1 (en)	2021-08-24	2023-03-02	Irena RABE	In vitro transcription technologies
WO2023034856A1 (en) *	2021-08-31	2023-03-09	New York University	COMPOSITIONS AND METHODS FOR SWITCHING ANTIBIOTIC RESISTANCE MARKERS PROGRESSIVELY FOR INTEGRATION (mSwAP-In)
WO2023031394A1 (en)	2021-09-03	2023-03-09	CureVac SE	Novel lipid nanoparticles for delivery of nucleic acids
WO2023031392A2 (en)	2021-09-03	2023-03-09	CureVac SE	Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
CA3231523A1 (en)	2021-09-14	2023-03-23	Renagade Therapeutics Management Inc.	Acyclic lipids and methods of use thereof
TW202328067A (zh)	2021-09-14	2023-07-16	美商雷納嘉德醫療管理公司	環狀脂質及其使用方法
US20230190806A1 (en)	2021-10-06	2023-06-22	Immatics Biotechnologies Gmbh	Methods of treating metastatic lesions and compositions thereof
CA3234127A1 (en)	2021-10-08	2023-04-13	Suzhou Abogen Biosciences Co., Ltd.	Lipid compounds and lipid nanoparticle compositions
AR127312A1 (es)	2021-10-08	2024-01-10	Suzhou Abogen Biosciences Co Ltd	Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
CN116064598B (zh)	2021-10-08	2024-03-12	苏州艾博生物科技有限公司	冠状病毒的核酸疫苗
WO2023064612A2 (en)	2021-10-15	2023-04-20	BioNTech SE	Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023069498A1 (en)	2021-10-22	2023-04-27	Senda Biosciences, Inc.	Mrna vaccine composition
EP4422698A1 (en)	2021-10-29	2024-09-04	CureVac SE	Improved circular rna for expressing therapeutic proteins
WO2023092069A1 (en)	2021-11-18	2023-05-25	Modernatx, Inc.	Sars-cov-2 mrna domain vaccines and methods of use
KR20240107356A (ko)	2021-11-23	2024-07-09	세일 바이오메디슨스, 인크.	박테리아-유래 지질 조성물 및 이의 용도
US12186387B2 (en)	2021-11-29	2025-01-07	BioNTech SE	Coronavirus vaccine
JP2024545152A (ja)	2021-12-08	2024-12-05	モデルナティエックスインコーポレイテッド	単純ヘルペスウイルスｍＲＮＡワクチン
WO2023122080A1 (en)	2021-12-20	2023-06-29	Senda Biosciences, Inc.	Compositions comprising mrna and lipid reconstructed plant messenger packs
EP4452928A1 (en)	2021-12-23	2024-10-30	Renagade Therapeutics Management Inc.	Constrained lipids and methods of use thereof
CN116332830A (zh)	2021-12-23	2023-06-27	苏州艾博生物科技有限公司	脂质化合物和脂质纳米颗粒组合物
WO2023144193A1 (en)	2022-01-25	2023-08-03	CureVac SE	Mrnas for treatment of hereditary tyrosinemia type i
WO2023147090A1 (en)	2022-01-27	2023-08-03	BioNTech SE	Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2023144330A1 (en)	2022-01-28	2023-08-03	CureVac SE	Nucleic acid encoded transcription factor inhibitors
EP4482962A1 (en)	2022-02-24	2025-01-01	IO Biotech ApS	Nucleotide delivery of cancer therapy
AU2023251104A1 (en)	2022-04-07	2024-10-17	Renagade Therapeutics Management Inc.	Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
WO2023196914A1 (en)	2022-04-08	2023-10-12	Modernatx, Inc.	Influenza nucleic acid compositions and uses thereof
WO2023213990A1 (en)	2022-05-05	2023-11-09	Etherna Immunotherapies Nv	Multi-epitope construct
AU2023268051A1 (en)	2022-05-13	2025-01-02	BioNTech SE	Rna compositions targeting hiv
WO2023230481A1 (en)	2022-05-24	2023-11-30	Modernatx, Inc.	Orthopoxvirus vaccines
AU2023277551A1 (en)	2022-05-25	2024-12-05	BioNTech SE	Rna compositions for delivery of monkeypox antigens and related methods
WO2023227608A1 (en)	2022-05-25	2023-11-30	Glaxosmithkline Biologicals Sa	Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
WO2023249934A1 (en) *	2022-06-20	2023-12-28	The Board Of Trustees Of The Leland Stanford Junior University	Methods of genetically modifying cells for altered codon-anti-codon interactions
US11878055B1 (en)	2022-06-26	2024-01-23	BioNTech SE	Coronavirus vaccine
WO2024015890A1 (en)	2022-07-13	2024-01-18	Modernatx, Inc.	Norovirus mrna vaccines
WO2024020346A2 (en)	2022-07-18	2024-01-25	Renagade Therapeutics Management Inc.	Gene editing components, systems, and methods of use
WO2024023246A1 (en)	2022-07-28	2024-02-01	Philogen S.P.A.	Antibody binding to pd1
WO2024033362A1 (en)	2022-08-08	2024-02-15	Atb Therapeutics	Humanized antibodies against cd79b
WO2024037578A1 (en)	2022-08-18	2024-02-22	Suzhou Abogen Biosciences Co., Ltd.	Composition of lipid nanoparticles
WO2024050483A1 (en)	2022-08-31	2024-03-07	Modernatx, Inc.	Variant strain-based coronavirus vaccines and uses thereof
WO2024064934A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of plasmodium csp antigens and related methods
WO2024064931A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of liver stage antigens and related methods
WO2024063788A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of malaria antigens and related methods
WO2024063789A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of malaria antigens and related methods
WO2024068545A1 (en)	2022-09-26	2024-04-04	Glaxosmithkline Biologicals Sa	Influenza virus vaccines
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024083345A1 (en)	2022-10-21	2024-04-25	BioNTech SE	Methods and uses associated with liquid compositions
US12186389B2 (en)	2022-10-28	2025-01-07	Glaxosmithkline Biologicals Sa	Nucleic acid base vaccine against emerging SARS-CoV-2 variants
WO2024089229A1 (en)	2022-10-28	2024-05-02	CureVac SE	Improved formulations comprising lipid-based carriers encapsulating rna
WO2024097874A1 (en)	2022-11-03	2024-05-10	Modernatx, Inc.	Chemical stability of mrna
GB202216449D0 (en)	2022-11-04	2022-12-21	Io Biotech Aps	TGF-BETA1 vaccine
WO2024102434A1 (en)	2022-11-10	2024-05-16	Senda Biosciences, Inc.	Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
DE102022213056A1 (de) *	2022-12-05	2024-06-06	Universität Rostock, Körperschaft des öffentlichen Rechts	Innovative antimikrobielle Therapie gegen Streptococcus pneumoniae mittels mRNA kodierter Bakteriophagen-Endolysine/Autolysine
EP4491230A1 (en)	2023-07-14	2025-01-15	iOmx Therapeutics AG	Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024133940A2 (en)	2022-12-23	2024-06-27	Iomx Therapeutics Ag	Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024141955A1 (en)	2022-12-28	2024-07-04	BioNTech SE	Rna compositions targeting hiv
US20240252520A1 (en)	2023-01-09	2024-08-01	Beth Israel Deaconess Medical Center, Inc.	Therapeutic agents and their use for treating chronic wounds
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
US20240238473A1 (en)	2023-01-09	2024-07-18	Beth Israel Deaconess Medical Center, Inc.	Recombinant nucleic acid molecules and their use in wound healing
WO2024151811A1 (en)	2023-01-11	2024-07-18	Modernatx, Inc.	Personalized cancer vaccines
TW202434263A (zh)	2023-01-27	2024-09-01	德商拜恩技術股份公司	用於遞送單純疱疹病毒醣蛋白ｃ、醣蛋白ｄ、及醣蛋白ｅ抗原之醫藥組成物及相關方法
WO2024159172A1 (en)	2023-01-27	2024-08-02	Senda Biosciences, Inc.	A modified lipid composition and uses thereof
WO2024163465A1 (en)	2023-01-30	2024-08-08	Modernatx, Inc.	Epstein-barr virus mrna vaccines
WO2024160936A1 (en)	2023-02-03	2024-08-08	Glaxosmithkline Biologicals Sa	Rna formulation
GB202302092D0 (en)	2023-02-14	2023-03-29	Glaxosmithkline Biologicals Sa	Analytical method
WO2024184500A1 (en)	2023-03-08	2024-09-12	CureVac SE	Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024189146A1 (en)	2023-03-15	2024-09-19	Versameb Ag	Rna encoding a protein
WO2024192277A2 (en)	2023-03-15	2024-09-19	Renagade Therapeutics Management Inc.	Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en)	2023-03-15	2024-09-19	Renagade Therapeutics Management Inc.	Delivery of gene editing systems and methods of use thereof
WO2024206835A1 (en)	2023-03-30	2024-10-03	Modernatx, Inc.	Circular mrna and production thereof
WO2024215721A1 (en)	2023-04-10	2024-10-17	Modernatx, Inc.	Lyme disease vaccines
WO2024220712A2 (en)	2023-04-19	2024-10-24	Sail Biomedicines, Inc.	Vaccine compositions
WO2024223728A1 (en)	2023-04-27	2024-10-31	Glaxosmithkline Biologicals Sa	Influenza virus vaccines
WO2024223724A1 (en)	2023-04-27	2024-10-31	Glaxosmithkline Biologicals Sa	Influenza virus vaccines
WO2024230934A1 (en)	2023-05-11	2024-11-14	CureVac SE	Therapeutic nucleic acid for the treatment of ophthalmic diseases
WO2024235451A1 (en)	2023-05-16	2024-11-21	CureVac RNA Printer GmbH	Improved rna in vitro transcription using dna beads
WO2024245907A1 (en)	2023-05-26	2024-12-05	CureVac SE	Cancer antigens
WO2024263826A1 (en)	2023-06-22	2024-12-26	Modernatx, Inc.	Sars-cov-2 t cell vaccines
WO2024260570A1 (en)	2023-06-23	2024-12-26	CureVac SE	Nucleic acid encoded antibodies
WO2025019352A2 (en)	2023-07-14	2025-01-23	Modernatx, Inc.	Mers-cov mrna vaccines
WO2025024335A2 (en)	2023-07-21	2025-01-30	BioNTech SE	Compositions for delivery of plasmodium antigens and related methods
WO2025024324A1 (en)	2023-07-21	2025-01-30	BioNTech SE	Compositions for delivery of plasmodium antigens and related methods
WO2025024337A1 (en)	2023-07-24	2025-01-30	BioNTech SE	Compositions for delivery of plasmodium antigens and related methods
WO2025029700A1 (en)	2023-07-28	2025-02-06	Modernatx, Inc.	Vlp enteroviral vaccines
WO2025027060A1 (en)	2023-07-31	2025-02-06	CureVac SE	Nucleic acid encoded runx3 transcription factor
WO2025027579A2 (en)	2023-08-03	2025-02-06	BioNTech SE	Rna compositions targeting hiv
WO2025027576A2 (en)	2023-08-03	2025-02-06	BioNTech SE	Rna compositions targeting hiv
WO2025030154A1 (en)	2023-08-03	2025-02-06	The Trustees Of The University Of Pennsylvania	Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods
WO2025030134A1 (en)	2023-08-03	2025-02-06	The Trustees Of The University Of Pennsylvania	Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
WO2025030103A1 (en)	2023-08-03	2025-02-06	The Trustees Of The University Of Pennsylvania	Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
WO2025030097A2 (en)	2023-08-03	2025-02-06	BioNTech SE	Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2025034612A1 (en)	2023-08-04	2025-02-13	Modernatx, Inc.	Varicella-zoster virus mrna vaccine
WO2025036992A1 (en)	2023-08-16	2025-02-20	CureVac SE	Rna conjugates
GB202404607D0 (en)	2024-03-29	2024-05-15	Glaxosmithkline Biologicals Sa	RNA formulation

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3906092A (en) *	1971-11-26	1975-09-16	Merck & Co Inc	Stimulation of antibody response
US5132418A (en)	1980-02-29	1992-07-21	University Patents, Inc.	Process for preparing polynucleotides
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4500707A (en)	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en)	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US4401796A (en)	1981-04-30	1983-08-30	City Of Hope Research Institute	Solid-phase synthesis of polynucleotides
US4373071A (en)	1981-04-30	1983-02-08	City Of Hope Research Institute	Solid-phase synthesis of polynucleotides
US4588585A (en) *	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) *	1982-10-19	1988-04-12	Cetus Corporation	Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6173986A (ja) *	1984-09-19	1986-04-16	塩野義製薬株式会社	遺伝子コドン配列教習具
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US5116943A (en) *	1985-01-18	1992-05-26	Cetus Corporation	Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) *	1986-07-03	1991-05-21	Schering Corporation	Mammalian interleukin-4
US5091309A (en)	1986-01-16	1992-02-25	Washington University	Sindbis virus vectors
US5153319A (en)	1986-03-31	1992-10-06	University Patents, Inc.	Process for preparing polynucleotides
US4879111A (en) *	1986-04-17	1989-11-07	Cetus Corporation	Treatment of infections with lymphokines
US5047524A (en)	1988-12-21	1991-09-10	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5262530A (en)	1988-12-21	1993-11-16	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5082767A (en) *	1989-02-27	1992-01-21	Hatfield G Wesley	Codon pair utilization
DE69034078T2 (de)	1989-03-21	2004-04-01	Vical, Inc., San Diego	Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en)	1989-03-21	2001-04-10	Vical Incorporated	Induction of a protective immune response in a mammal by injecting a DNA sequence
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
SE9003978D0 (sv)	1990-12-13	1990-12-13	Henrik Garoff	Dna expressionssystem baserade paa ett virus replikon
EP0625049A4 (en)	1992-01-23	1995-07-12	Vical Inc	EX VIVO GENTRANSFER.
US6174666B1 (en) *	1992-03-27	2001-01-16	The United States Of America As Represented By The Department Of Health And Human Services	Method of eliminating inhibitory/instability regions from mRNA
EP0609739A1 (en)	1993-02-02	1994-08-10	American Cyanamid Company	Method of reversing immunosuppression in vaccines
DK0668350T4 (da) *	1994-02-16	2009-02-23	Us Gov Health & Human Serv	Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom
IL112820A0 (en)	1994-03-07	1995-05-26	Merck & Co Inc	Coordinate in vivo gene expression
US5965720A (en) *	1994-03-18	1999-10-12	Lynx Therapeutics, Inc.	Oligonucleotide N3'→P5' phosphoramidates
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
GB9406498D0 (en) *	1994-03-31	1994-05-25	Smithkline Beecham Biolog	Novel compounds
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5795737A (en) *	1994-09-19	1998-08-18	The General Hospital Corporation	High level expression of proteins
US5786464C1 (en) *	1994-09-19	2012-04-24	Gen Hospital Corp	Overexpression of mammalian and viral proteins
US5700642A (en)	1995-05-22	1997-12-23	Sri International	Oligonucleotide sizing using immobilized cleavable primers
US6051429A (en) *	1995-06-07	2000-04-18	Life Technologies, Inc.	Peptide-enhanced cationic lipid transfections
US6265387B1 (en) *	1995-10-11	2001-07-24	Mirus, Inc.	Process of delivering naked DNA into a hepatocyte via bile duct
US20030143204A1 (en) *	2001-07-27	2003-07-31	Lewis David L.	Inhibition of RNA function by delivery of inhibitors to animal cells
US6534312B1 (en) *	1996-02-22	2003-03-18	Merck & Co., Inc.	Vaccines comprising synthetic genes
US6090391A (en) *	1996-02-23	2000-07-18	Aviron	Recombinant tryptophan mutants of influenza
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0912607A2 (en)	1996-06-21	1999-05-06	Merck & Co., Inc.	Vaccines comprising synthetic genes
US6114148C1 (en)	1996-09-20	2012-05-01	Gen Hospital Corp	High level expression of proteins
US6610661B1 (en) *	1996-10-11	2003-08-26	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0839912A1 (en)	1996-10-30	1998-05-06	Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo)	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6204250B1 (en) *	1996-11-22	2001-03-20	The Mount Sinai Medical Center Of The City Of New York	Immunization of infants
EP0855184A1 (en) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
JP2001512308A (ja) *	1997-02-07	2001-08-21	メルクエンドカンパニーインコーポレーテッド	合成ｈｉｖｇａｇ遺伝子
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69840850D1 (de)	1997-06-06	2009-07-09	Dynavax Tech Corp	Inhibitoren von immunstimulatorischen dna sequenz aktivität
US6589940B1 (en) *	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
JP4434479B2 (ja) *	1997-07-09	2010-03-17	ザ・ユニバーシティ・オブ・クイーンズランド	標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
WO1999014346A2 (en)	1997-09-19	1999-03-25	Sequitur, Inc.	SENSE mRNA THERAPY
BR9812945A (pt) *	1997-10-20	2000-08-08	Genzyme Transgenics Corp	Sequências de ácido nucléico modificadas e processos para aumentar os nìveis de mrna e expressão de sistemas celulares
CA2641217A1 (en) *	1997-11-20	1999-06-03	Vical Incorporated	Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US6432925B1 (en)	1998-04-16	2002-08-13	John Wayne Cancer Institute	RNA cancer vaccine and methods for its use
IL125608A0 (en) *	1998-07-30	1999-03-12	Yeda Res & Dev	Tumor associated antigen peptides and use of same as anti-tumor vaccines
US20090042283A1 (en) *	1998-09-29	2009-02-12	Shire Human Genetic Therapies, Inc., A Delaware Corporation	Optimized messenger rna
US6924365B1 (en) *	1998-09-29	2005-08-02	Transkaryotic Therapies, Inc.	Optimized messenger RNA
US6734172B2 (en) *	1998-11-18	2004-05-11	Pacific Northwest Research Institute	Surface receptor antigen vaccines
EP1980617A1 (en) *	1998-12-31	2008-10-15	Novartis Vaccines and Diagnostics, Inc.	Improved expression of HIV polypeptides and production of virus-like particles
EP1141314A2 (en)	1998-12-31	2001-10-10	Chiron Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2000057910A1 (en) *	1999-03-26	2000-10-05	Walter Reed Army Institute Of Research	Attenuated dengue-4 virus vaccine
EP1165798A2 (en) *	1999-03-29	2002-01-02	Statens Serum Institut	Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
CA2376634A1 (en)	1999-06-08	2000-12-14	Aventis Pasteur	Immunostimulant oligonucleotide
US6514948B1 (en) *	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
AU783681B2 (en) *	1999-07-09	2005-11-24	Wyeth	Methods and compositions for preventing the formation of aberrant RNA during transcription of a plasmid sequence
AU772611B2 (en) *	1999-08-25	2004-05-06	Merck Sharp & Dohme Corp.	Synthetic human papillomavirus genes
US20050112141A1 (en) *	2000-08-30	2005-05-26	Terman David S.	Compositions and methods for treatment of neoplastic disease
US20040106567A1 (en) *	1999-09-07	2004-06-03	Hagstrom James E.	Intravascular delivery of non-viral nucleic acid
DE69943068D1 (de)	1999-09-09	2011-02-03	Curevac Gmbh	Transfer von mRNA unter Verwendung von polykationischen Verbindungen
AU7398200A (en)	1999-09-17	2001-04-24	Aventis Pasteur Limited	Chlamydia antigens and corresponding dna fragments and uses thereof
WO2002064799A2 (en)	1999-09-28	2002-08-22	Transkaryotic Therapies, Inc.	Optimized messenger rna
CA2398756A1 (en) *	2000-01-31	2001-08-02	Eyal Raz	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US20020142978A1 (en) *	2000-04-07	2002-10-03	Eyal Raz	Synergistic improvements to polynucleotide vaccines
JP2004530629A (ja)	2000-06-07	2004-10-07	バイオシネクサスインコーポレーテッド	免疫刺激ｒｎａ／ｄｎａハイブリッド分子
ES2273852T3 (es) *	2000-06-23	2007-05-16	Wyeth Holdings Corporation	Proteinas v de morbillivirus modificadas.
AU2001276619A1 (en) *	2000-07-03	2002-01-14	Chiron S.P.A.	Immunisation against chlamydia pneumoniae
AU2001275695B9 (en) *	2000-07-21	2005-05-26	Glaxo Group Limited	Codon-optimized papilloma virus sequences
GB0017990D0 (en) *	2000-07-21	2000-09-13	Glaxo Group Ltd	Papilloma virus sequences
US20030092145A1 (en) *	2000-08-24	2003-05-15	Vic Jira	Viral vaccine composition, process, and methods of use
US6733994B2 (en) *	2000-10-04	2004-05-11	The Trustees Of The University Of Pennsylvania	Highly expressible genes
CA2854685A1 (en)	2000-10-11	2002-08-22	Richard F Selden	Optimized messenger rna
US20030077604A1 (en) *	2000-10-27	2003-04-24	Yongming Sun	Compositions and methods relating to breast specific genes and proteins
US20020132788A1 (en) *	2000-11-06	2002-09-19	David Lewis	Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
AU2002242474B2 (en)	2001-03-09	2004-05-20	Gene Stream Pty Ltd	Novel expression vectors
AUPR446801A0 (en) *	2001-04-18	2001-05-17	University Of Queensland, The	Novel compositions and uses therefor
DE10119005A1 (de)	2001-04-18	2002-10-24	Roche Diagnostics Gmbh	Verfahren zur Proteinexpression ausgehend von stabilisierter linearer kurzer DNA in zellfreien in vitro-Transkription/Translations-Systemen mit Exonuklease-haltigen Lysaten oder in einem zellulären System enthaltend Exonukleasen
CN1302115C (zh) *	2001-04-23	2007-02-28	埃麦克萨有限公司	电穿孔用缓冲溶液及上述溶液的使用方法
WO2002087341A1 (en) *	2001-05-01	2002-11-07	Genetix Pharmaceuticals, Inc.	Novel self-inactivating (sin) lentiviral vectors
US20030232324A1 (en) *	2001-05-31	2003-12-18	Chiron Corporation	Chimeric alphavirus replicon particles
AU2002303330B2 (en) *	2001-05-31	2008-07-24	Novartis Vaccines And Diagnostics, Inc.	Chimeric alphavirus replicon particles
ES2340532T3 (es)	2001-06-05	2010-06-04	Curevac Gmbh	Arnm con un contenido g/c aumentado que codifica para un antigeno bacteriano y utilizacion del mismo.
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
US7547551B2 (en) *	2001-06-21	2009-06-16	University Of Antwerp.	Transfection of eukaryontic cells with linear polynucleotides by electroporation
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
DE10148886A1 (de) *	2001-10-04	2003-04-30	Avontec Gmbh	Inhibition von STAT-1
US7276489B2 (en) *	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
DE10162480A1 (de)	2001-12-19	2003-08-07	Ingmar Hoerr	Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en)	2002-01-18	2003-07-30	Curevac Gmbh	Immunogenic preparations and vaccines on the basis of mrna
CA2474709A1 (en)	2002-02-04	2003-08-14	Biomira, Inc.	Immunostimulatory, covalently lipidated oligonucleotides
GB0202569D0 (en) *	2002-02-04	2002-03-20	Oxford Biomedica Ltd	Delivery means
CA2481479C (en)	2002-02-26	2012-12-11	Maxygen, Inc.	Novel flavivirus antigens
EP3006043B1 (en)	2002-04-04	2019-05-29	Zoetis Belgium S.A.	Immunostimulatory g,u-containing oligoribonucleotides
US8012736B2 (en)	2002-04-26	2011-09-06	Medimmune, Llc	Multi plasmid system for the production of influenza virus
DE10229872A1 (de) *	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
DE60336736D1 (de) *	2002-07-16	2011-05-26	VGX Pharmaceuticals LLC	Codon-optimierte synthetische plasmide
EP1393745A1 (en)	2002-07-29	2004-03-03	Hybridon, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends
WO2004055161A2 (en) *	2002-12-12	2004-07-01	The Board Of Regents Of The University Of Texas System	Large scale production of packaged alphavirus replicons
WO2004058159A2 (en)	2002-12-23	2004-07-15	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
CA2522213A1 (en)	2003-04-08	2004-10-28	Dante J. Marciani	Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
DK176326B1 (da)	2003-05-14	2007-08-13	Smidth As F L	Indretning til at opdele en ström af partikel- eller pulverformet materiale i delströmme
DE10335833A1 (de) *	2003-08-05	2005-03-03	Curevac Gmbh	Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE102004035227A1 (de)	2004-07-21	2006-02-16	Curevac Gmbh	mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004042546A1 (de)	2004-09-02	2006-03-09	Curevac Gmbh	Kombinationstherapie zur Immunstimulation
AU2006241149A1 (en) *	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
ES2937245T3 (es)	2005-08-23	2023-03-27	Univ Pennsylvania	ARN que contiene nucleósidos modificados y métodos de uso del mismo
EP3041934A1 (en)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Chimeric polynucleotides

2002
- 2002-06-05 ES ES07002195T patent/ES2340532T3/es not_active Expired - Lifetime
- 2002-06-05 AT AT05004938T patent/ATE456959T1/de active
- 2002-06-05 DE DE50214200T patent/DE50214200D1/de not_active Expired - Lifetime
- 2002-06-05 EP EP20070023083 patent/EP1903054A3/de not_active Withdrawn
- 2002-06-05 EP EP05004938A patent/EP1604688B1/de not_active Expired - Lifetime
- 2002-06-05 AT AT07015835T patent/ATE490267T1/de active
- 2002-06-05 AT AT07002195T patent/ATE457029T1/de active
- 2002-06-05 EP EP07002195A patent/EP1832603B1/de not_active Expired - Lifetime
- 2002-06-05 EP EP02732752A patent/EP1392341B1/de not_active Expired - Lifetime
- 2002-06-05 DK DK07015835T patent/DK1857122T3/da active
- 2002-06-05 DE DE50214201T patent/DE50214201D1/de not_active Expired - Lifetime
- 2002-06-05 DE DE50202634T patent/DE50202634D1/de not_active Expired - Lifetime
- 2002-06-05 ES ES05004938T patent/ES2340499T3/es not_active Expired - Lifetime
- 2002-06-05 CA CA2457959A patent/CA2457959C/en not_active Expired - Fee Related
- 2002-06-05 EP EP10007991.2A patent/EP2305699B1/de not_active Expired - Lifetime
- 2002-06-05 AT AT02732752T patent/ATE291925T1/de active
- 2002-06-05 DE DE50214801T patent/DE50214801D1/de not_active Expired - Lifetime
- 2002-06-05 EP EP20070000343 patent/EP1800697B1/de not_active Expired - Lifetime
- 2002-06-05 EP EP20140002635 patent/EP2842964A1/de not_active Withdrawn
- 2002-06-05 ES ES07000343T patent/ES2344078T3/es not_active Expired - Lifetime
- 2002-06-05 EP EP07015835A patent/EP1857122B1/de not_active Expired - Lifetime
- 2002-06-05 AT AT07000343T patent/ATE464317T1/de active
- 2002-06-05 ES ES07015835T patent/ES2356934T3/es not_active Expired - Lifetime
- 2002-06-05 WO PCT/EP2002/006180 patent/WO2002098443A2/de active IP Right Grant
- 2002-06-05 PT PT07015835T patent/PT1857122E/pt unknown
- 2002-06-05 ES ES02732752T patent/ES2240745T3/es not_active Expired - Lifetime
- 2002-06-05 DE DE50214379T patent/DE50214379D1/de not_active Expired - Lifetime
- 2002-06-05 CA CA2830887A patent/CA2830887C/en not_active Expired - Fee Related
2003
- 2003-12-05 US US10/729,830 patent/US10188748B2/en active Active
2007
- 2007-07-10 AU AU2007203181A patent/AU2007203181B2/en not_active Ceased
2009
- 2009-07-16 AU AU2009202873A patent/AU2009202873B2/en not_active Ceased
2010
- 2010-05-26 US US12/787,755 patent/US20100239608A1/en not_active Abandoned
- 2010-05-26 US US12/787,566 patent/US20110077287A1/en not_active Abandoned
2011
- 2011-07-18 US US13/185,119 patent/US20110269950A1/en not_active Abandoned
2014
- 2014-09-16 US US14/487,425 patent/US11135312B2/en active Active
2016
- 2016-01-13 US US14/994,913 patent/US20230181765A2/en not_active Abandoned
- 2016-01-25 US US15/005,863 patent/US20160136263A1/en not_active Abandoned
- 2016-01-25 US US15/005,911 patent/US20160136258A1/en not_active Abandoned
- 2016-01-25 US US15/005,950 patent/US10568972B2/en not_active Expired - Lifetime
- 2016-01-25 US US15/005,753 patent/US20160136243A1/en not_active Abandoned
- 2016-01-25 US US15/005,986 patent/US11369691B2/en not_active Expired - Lifetime
- 2016-01-25 US US15/005,808 patent/US20160136247A1/en not_active Abandoned
- 2016-08-26 US US15/248,902 patent/US20160361438A1/en not_active Abandoned
2018
- 2018-08-29 US US16/116,320 patent/US20190134222A1/en not_active Abandoned
2021
- 2021-02-15 FR FR21C1007C patent/FR21C1007I1/fr active Active
- 2021-02-15 FR FR21C1008C patent/FR21C1008I1/fr active Active

Also Published As

Publication number	Publication date
EP1857122A3 (de)	2008-11-19
US20160136243A1 (en)	2016-05-19
AU2007203181A1 (en)	2007-07-26
EP1903054A2 (de)	2008-03-26
ES2240745T3 (es)	2005-10-16
US20190134222A1 (en)	2019-05-09
EP1800697A2 (de)	2007-06-27
EP1800697B1 (de)	2010-04-14
EP1604688B1 (de)	2010-02-03
ES2356934T3 (es)	2011-04-14
US20160136247A1 (en)	2016-05-19
US20160129105A1 (en)	2016-05-12
US20160136259A1 (en)	2016-05-19
US11135312B2 (en)	2021-10-05
EP1857122A2 (de)	2007-11-21
FR21C1008I1 (fr)	2021-03-26
US20110269950A1 (en)	2011-11-03
CA2457959A1 (en)	2002-12-12
ATE291925T1 (de)	2005-04-15
US10188748B2 (en)	2019-01-29
DK1857122T3 (da)	2011-03-21
EP1857122B1 (de)	2010-12-01
PT1857122E (pt)	2011-03-07
EP2305699B1 (de)	2014-08-13
EP1903054A3 (de)	2008-07-23
CA2830887A1 (en)	2002-12-12
ES2344078T3 (es)	2010-08-17
EP1392341B1 (de)	2005-03-30
ATE464317T1 (de)	2010-04-15
EP1800697A3 (de)	2007-10-31
DE50214200D1 (de)	2010-03-25
ATE456959T1 (de)	2010-02-15
ATE457029T1 (de)	2010-02-15
US10568972B2 (en)	2020-02-25
EP1832603A3 (de)	2007-10-31
DE50214201D1 (de)	2010-03-25
WO2002098443A2 (de)	2002-12-12
US20160361438A1 (en)	2016-12-15
EP1832603A2 (de)	2007-09-12
US20230181765A2 (en)	2023-06-15
US20100239608A1 (en)	2010-09-23
US20160136263A1 (en)	2016-05-19
DE50214379D1 (de)	2010-05-27
AU2009202873A1 (en)	2009-08-06
CA2830887C (en)	2016-11-29
US20160136258A1 (en)	2016-05-19
AU2009202873B2 (en)	2012-08-16
EP2305699A1 (de)	2011-04-06
ATE490267T1 (de)	2010-12-15
ES2340532T3 (es)	2010-06-04
EP1392341A2 (de)	2004-03-03
US20110077287A1 (en)	2011-03-31
AU2007203181B2 (en)	2011-01-06
DE50202634D1 (de)	2005-05-04
WO2002098443A3 (de)	2003-11-13
EP2842964A1 (de)	2015-03-04
CA2457959C (en)	2014-10-28
ES2340499T3 (es)	2010-06-04
US11369691B2 (en)	2022-06-28
EP1832603B1 (de)	2010-02-03
US20050032730A1 (en)	2005-02-10
AU2009202873A8 (en)	2009-08-13
DE50214801D1 (de)	2011-01-13
US20150104476A1 (en)	2015-04-16
EP1604688A1 (de)	2005-12-14
US20160136301A1 (en)	2016-05-19

Publication	Publication Date	Title
FR21C1007I1 (fr)	2021-03-26	Arnm stabilise avec un contenu augmente en g/c, codant pour un antigene virale
MXPA03006238A (es)	2003-09-22	Combustion baja de nox con oxigeno mejorado.
MXPA03004761A (es)	2003-08-19	Turboalimentador sin alabes.
ITRM20010537A0 (it)	2001-09-06	Motociclo.
MXPA01011516A (es)	2003-08-20	Incinerador de pared radiante de bajo nox.
BR0110375B1 (pt)	2010-06-29	compressor.
BR0100991B1 (pt)	2009-01-13	montagem de bombeamento de combustÍvel.
HK1058989A1 (en)	2004-06-11	Violin shoulder cradle.
ITRM20010523A0 (it)	2001-08-30	Motociclo.
NO20042473L (no)	2004-06-14	Ventilplugg.
BR0208469B1 (pt)	2013-02-05	isqueiro.
BR0115125B1 (pt)	2010-07-27	acendedor.
EG23395A (en)	2005-05-31	Stabilised hypobromous acid solutions.
BR0204153B1 (pt)	2010-10-19	transmissão.
GB2382624B (en)	2004-04-07	High flow fuel pump
BR0204480B1 (pt)	2010-09-21	válvula com filtro.
BR0101022B1 (pt)	2009-08-11	motocicleta.
ITTO20020348A1 (it)	2003-10-22	Motociclo.
ITTO20010846A0 (it)	2001-09-05	Motociclo.
ES1049150Y (es)	2002-03-16	Un tirante.
NL1021007A1 (nl)	2003-03-03	Beugelslot.
Bierbrier et al.	2000	Resource Centre
沈江	2001	Are You Ready?
IT1315989B1 (it)	2003-03-26	Salpa ancora e galleggiamento.
ES1046008Y (es)	2001-12-01	Linterna.